You're contacting media contact of this press release

Title: BulkGLP Launches Mannitol-Free Bulk Retatrutide for Research Labs in 2025

United States, 24th Jul 2025 – BulkGLP, a leading supplier of high-purity research peptides, has announced the launch of mannitol-free Bulk Retatrutide, now available in wholesale quantities for research laboratories, clinical facilities, and authorized resellers.This new formulation offers 98%+ purity with zero excipients, providing researchers with a cleaner, more stable compound for long-term studies on obesity, metabolic health, and glucose regulation. By removing mannitol, a common filler used in many peptide formulations, BulkGLP is meeting the growing demand for unadulterated Retatrutide that delivers consistency and precision for sensitive research environments.Retatrutide: The Next-Generation Research PeptideRetatrutide is a triple agonist peptide that simultaneously activates GLP-1, GIP, and glucagon receptors. This unique mechanism has shown remarkable potential in clinical trials, achieving superior weight loss and metabolic improvements compared to existing dual agonists like Tirzepatide and single agonists like Semaglutide.With its ability to influence multiple pathways involved in appetite regulation, glucose metabolism, and energy balance, Retatrutide has quickly become one of the most sought-after peptides in advanced obesity and diabetes research.As interest in this compound accelerates, research labs worldwide are seeking reliable sources of high-purity Retatrutide in larger quantities. BulkGLP’s new mannitol-free bulk Retatrutide offering meets this demand with superior quality and batch consistency.Why Mannitol-Free Retatrutide MattersMany peptide suppliers rely on mannitol as an inexpensive excipient to improve lyophilization and handling. However, for sensitive research applications, fillers like mannitol can:Introduce unnecessary variability in e...

This press release is issued by King Newswire